AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has initiated another Phase 1b clinical study for its lead product candidate, the novel triple VEGF receptor inhibitor AV-951. Continue reading ...
An effective new method of diagnosing bowel (also known as colorectal, or large bowel) cancer using 'light' may soon be available, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester. The technique, known as 'photodynamic diagnosis', is already used to diagnose and treat other types of cancers, for example, certain skin cancers. Continue reading ...
VIROLOGY: HIV-stimulated immune cells generate cells with immunosuppressive properties Nina Bhardwaj and colleagues, at New York University, have provided new insight into the role of human immune cells known as plasmacytoid dendritic cells (pDCs) in the anti-HIV immune response. When pDCs interact with HIV they become activated, secreting large amounts of the soluble factor IFN-alpha, which is a key component of the anti-HIV immune response. Continue reading ...
Cutting-edge discoveries in ovarian cancer research including developments on improving therapeutics for patients diagnosed with ovarian cancer and early detection of the disease were revealed as the 7th Biennial Ovarian Cancer Research Symposium came to a close Friday afternoon. The two-day symposium covered all aspects of ovarian cancer research, but some of the most exciting included Dr. Continue reading ...
A new mouse model has provided some surprising insight into XLF, a molecule that helps to repair lethal DNA damage. The research, published by Cell Press in the September 5th issue of the journal Molecular Cell, suggests that although XLF shares many properties with well known DNA repair factors, certain cells of the immune system possess an unexpected compensatory mechanism that that can take over for nonfunctional XLF. Continue reading ...
Promising targets for drug development Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in Science magazine. Continue reading ...
Children's Cancer Research Fund® and partners Ronald McDonald Charities Upper Midwest, HopeKids Twin Cities and Gilda's Club announce the launch of CompleteTheCure.com, an interactive website designed to educate the public on the childhood cancer experience, introduce doctors who are make progress in the treatment and cure of childhood cancer as well as share the inspirational stories of children with cancer. Continue reading ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment